Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

137 results about "B polymyxin" patented technology

Polymyxin B is an antibiotic primarily used for resistant Gram-negative infections. It is derived from the bacterium Bacillus polymyxa. Polymyxin B is composed of a number of related compounds (see "Mixture composition").

Method for detecting residual quantity of multiple polypeptidepolypeptide veterinary drugs in animal-derived food

The invention relates to the fields of analytical chemistry and food safety, particular to a method for detecting the residual quantity of multiple polypeptide veterinary drugs in animal-derived foods. The method comprises the following steps of: processing a sample with a TCA(trichloroacetic acid) and acetonitrile system for depositing proteins; extracting with a carbinol and 0.1% formic acid aqueous solution system; purifying with a Oasis HLB solid phase extraction column; performing gradient elution with an Eclipse XDB-C18 analytical column in the presence of an acetonitrile and 0.1% formic acid aqueous solution used as a mobile phase; and then performing electrospray and positive ion scanning mode separation for finally detecting four polypeptides. The limits of the four polypeptides, namely colistin, bacitracin A, polymyxin B and virginiamycin M, are 25 micrograms/kilogram, 100 micrograms/kilogram, 250 micrograms/kilogram and 120 micrograms/kilogram respectively; the recovery rates of colistin, bacitracin A, polymyxin B and virginiamycin M are 74.9-88.1%, 76.2-89.0%, 76.6-81.2% and 77.3-86.9% respectively; and the coefficients of variation (CV%) of colistin, bacitracin A, polymyxin B and virginiamycin M are 5.7-15.1%, 7.2-15.7%, 6.0-8.0% and 9.5-18.6% respectively. The detection limit, the recovery rate, the accuracy and other technical indexes all meet related detection requirements at home and aboard.
Owner:林维宣

Preparing method of high-purity polymyxin B

The invention discloses a preparing method of high-purity polymyxin B. The preparing method comprises the steps of preparation of column-loading solution; injecting the column-loading solution into a high performance liquid chromatography preparative column, wherein sodium sulfate - phosphate buffer / organic solvent is used as mobile phase, collecting target components, removing impurities, especially B1 - 1 and B3, and determining collected solution by means of high performance liquid chromatography (HPLC), wherein chromatographic purity of the target components B1 or B2 or mixture of the B1 and the B2 is more than 99.5%; and purification, wherein vacuum concentration is carried out on the collected target components so that the organic solvent is removed, organic solvent desalination concentration is carried out on balance phase, concentrated solution is spray-dried or freeze-dried to produce the polymyxin B with purity of more than 99.5%. The preparing method of the high-purity polymyxin B has the advantages of being high in purity, high in yield, simple in process, and capable of injecting sample solution continuously. Quality of products is far better than the medical standard regulated by the European Pharmacopoeia (EP) and the United States Pharmacopeia (USP). One-time investment of equipment is slightly high, while operation cost is not high, and therefore the preparing method of the high-purity polymyxin B is suitable for industrial production.
Owner:HUBEI RUIHAO ANKE MEDICINE TECH DEV CO LTD

Method for extracting polymyxin B and E from fermentation technique culture

InactiveCN101974075AHigh yieldProduction cost caused by high yield and lowPolymyxinsPeptide preparation methodsSeparation technologySolvent
The invention relates to a method for extracting polymyxin B and E from a fermentation technique culture, which comprises the following steps of: adjusting the pH value of the fermentation technique culture to 10.0 to 14.0 by utilizing an alkaline substance under the temperature of 0 to 25 DEG C and then stirring for 30 min; collecting fungus dregs by utilizing a solid-liquid separation technique to obtain a polymyxin B and E free alkali precipitate; adjusting the pH value of the free alkali precipitate obtained by the solid-liquid separation technique to 1.0 to 6.0 by using an acid substance or solution; after the polymyxin B and E free alkali precipitate is dissolved, carrying out solid-liquid separation to obtain the concentrated solution of polymyxin B and E salts; removing inorganic salts by using a nanofiltration technology; and finally carrying out spray drying to obtain the finished product. The method is characterized by extracting the polymyxin B and E from fermentation liquor in a convenient and high-efficiency mode, solves the problem of high production cost because of high labor strength, long working procedure and low extraction yield in the production process of other extraction methods, and has the advantages of no use of solvents, low cost, environment protection, high yield and low characteristic requirements on the fermentation liquor and equipment.
Owner:SHANDONG LUKANG PHARMA

Method for extracting polymyxin B from fermentation broth

The invention discloses a method for extracting polymyxin B from a fermentation broth of the polymyxin B. The method for extracting the polymyxin B from the fermentation broth of the polymyxin B comprises the following steps: a, conducting solid-liquid separation on the fermentation broth of the polymyxin B and obtaining a filtrate; b, extracting the filtrate with a polar organic solvent, and extracting an extract liquor reversely with water when the extract liquor is at the potential hydrogen (pH) value of 1.0-2.0; c, adding the reversal extract liquor which is obtained from the step b into inorganic salt, wherein the volume of the reversed extract liquor of the inorganic salt is 3-8% (w/v), and adjusting the pH value to be 9.0-10.0 so that the polymyxin B is obtained after precipitation and sediment. Preferably, the method for extracting the polymyxin B from the fermentation broth further comprises a step of d: reacting the polymyxin B and sulfuric acid to form salt, and dissolving and precipitating, thereby obtaining the polymyxin B sulfate. The polymyxin B or the sulfate prepared by means of the method is higher in yield and purity, the purity of a product is above 85%, the tilter is above 8100IU/g, and the yield is above 60%. The method for extracting polymyxin B from the fermentation broth has the advantages of being easy and convenient to operate, short in time consuming, low in requirement of equipment, and capable of recycling the organic solvent and being used for large-scale industrial production.
Owner:SHANGHAI INST OF PHARMA IND +1

Application of pithecellobium clypearia extracts to preparation of multi-drug resistant acinetobacter baumannii medicine

The invention discloses application of pithecellobium clypearia extracts to preparation of multi-drug resistant acinetobacter baumannii medicine. The pithecellobium clypearia extracts are prepared through the method includes the steps that pithecellobium clypearia coarse powder is extracted with water or an ethyl alcohol solution, the obtained extraction liquid is extracted with ethyl acetate, and the obtained extracts are target products. The antibacterial function of the pithecellobium clypearia extracts to multi-drug resistant acinetobacter baumannii and the sensitivity enhancing function of the pithecellobium clypearia extracts to similar antibiotics are disclosed for the first time. Tests prove that the pithecellobium clypearia extracts and imipenem or tetracycline or polymyxin B or ceftazidime or levofloxacin take effect together, and the use amount of antibiotics can be reduced by 50-87% compared with the mode that only the pithecellobium clypearia extracts are used. The pithecellobium clypearia extracts can serve as natural multi-drug resistant acinetobacter baumannii medicine or an antibiotic sensitivity-enhancing agent, and is applied to treatment of diseases caused by acinetobacter baumannii. A new means and alternative medicine are provided for solving the drug resistance problem of similar antibiotics.
Owner:HUACHENG PHARMA FACTORY GAUNGZHOU

Factor c for treating gram-negative bacterial infection

Recombinant fragments of Factor C are disclosed. These proteins and peptides show great potency in recognizing, binding to, neutralizing and removing endotoxin. These molecules can thus be used for anti-microbial, anti-endotoxin, and anti-sepsis therapy. SSCrFCES is a 38 kDa protein representing the LPS-binding domain of Factor C. The ability of SSCrFCES to bind lipid A was analyzed using an ELISA-based assay as well as surface plasmon resonance. Surface plasmon resonance similarly carried out for SSCrFC-sushi-1,2,3-GFP, SSCrFC-sushi-1GFP, and SSCrFC-sushi-3GFP confirmed their superior affinity for endotoxin. The 50% endotoxin-neutralizing concentration of SSCrFCES against 200 EU of endotoxin is 0.069 μM, suggesting that SSCrFCES is an effective inhibitor of LAL coagulation cascade. Although partially attenuated by human serum, as low as 1 μM of SSCrFCES inhibits the LPS-induced secretion of hTNF-α and hIL-8 by THP-1 and human pheripheral blood mononuclear cells with a potency more superior than polymyxin B. SSCrFCES is non-cytotoxic, with a clearance rate of 4.7 ml / minute. The LD90 of SSCrFCES for LPS lethality in mice is achieved at 2 μM. These results demonstrate the endotoxin-neutralizing capability of SSCrFCES in vitro and in vivo, as well as its potential for use in the treatment of endotoxin-induced septic shock. Also embodied in this application is the use of the sushi peptides and their mutant derivatives as potent antimicrobials.
Owner:NAT UNIV OF SINGAPORE

Preparation method of water-soluble alginate for in-vivo implantation

The invention relates to the technical field of natural polysaccharides for in-vivo implantation, in particular to a preparation method of water-soluble alginate for in-vivo implantation. The preparation method comprises the following steps of: taking commercially available food-grade or pharmaceutical adjuvant-grade water-soluble alginate as a raw material, performing microporous filtration and multistage activated carbon adsorption, and then acidifying to form gel; eluting the gel with an alkaline solution for redissolving the gel, and adsorbing the gel with polymyxin B agarose; and separating out alginate with an organic solution in a sterile environment, and vacuum drying to obtain sodium alginate for in- vivo implantation. According to the invention, the synergistic effects of physical adsorption, affinity adsorption and chemical chelation are utilized to remove impurities such as foreign proteins, endotoxin and the like, impurity ions are not introduced in the preparation process, adverse effects of ion residues on product quality are avoided, and the obtained alginate has high purity and can be implanted in vivo; a folded membrane filter element and activated carbon adsorption are used to complete microporous filtration of high viscosity liquid; a two-fluid nozzle is adopted for dispersion granulation, and the method is suitable for industrial batch production.
Owner:QINGDAO BRIGHT MOON ALGINATE TISSUE ENG MATERIAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products